NASDAQ · Financial Statements
Agile Therapeutics, Inc. (AGRX) Financial Statements
$1.51
NASDAQ: AGRX
Market Cap $10.43M
Overview Financials Dividend Agile Therapeutics, Inc. most recently reported annual revenue of $20.0M, net profit of $-14.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023 Revenue $0 $1.0M $4.0M $11.0M $20.0M Operating Profit $-19.0M $-49.0M $-71.0M $-41.0M $-20.0M Net Profit $-18.0M $-55.0M $-77.0M $-25.0M $-14.0M EPS $-746.20 $-1291.56 $-63115.49 $-58.79 $-6.71 Op Margin — -6549.1% -1731.4% -380.7% -101.5%
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023 Total Assets $50.0M $73.0M $39.0M $14.0M $10.0M Total Liabilities $4.0M $24.0M $30.0M $20.0M $27.0M Cash $34.0M $14.0M $19.0M $5.0M $3.0M Borrowings $0 $17.0M $18.0M $2.0M $2.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023 Operating Cash Flow $-16.0M $-47.0M $-65.0M $-36.0M $-10.0M Investing Cash Flow $0 $-41.0M $79.0M $0 $0 Financing Cash Flow $42.0M $0 $0 $0 $15.0M Net Cash Flow $27.0M $-20.0M $5.0M $-14.0M $-3.0M Free Cash Flow $-16.0M $-48.0M $-65.0M $-36.0M $-10.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -0.79 FCF Yield -91.86% Quick Ratio 0.33 Interest Coverage -14.01 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock